Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arecor Therapeutics PLC ( (GB:AREC) ) has provided an announcement.
Arecor Therapeutics will showcase its lead diabetes programme at two major industry conferences in March, underscoring its bid to position AT278 as a disruptive insulin therapy. The company will present AT278, described as the only ultra-concentrated, ultra-rapid acting insulin designed for use with automated insulin delivery systems, at the virtual Oppenheimer Healthcare MedTech & Services Conference on 16 March, with CEO Sarah Howell leading the session and senior executives also in attendance.
In parallel, Arecor’s leadership team will attend the Advanced Technologies & Treatments for Diabetes conference in Barcelona from 11–14 March, a key forum that convenes clinicians, industry, investors and regulators around advances in diabetes care. The dual conference presence is intended to build visibility among clinical, commercial and investor stakeholders for AT278’s potential to meet high daily insulin needs and enable next-generation miniaturised automated insulin delivery devices, reinforcing Arecor’s strategic focus in the diabetes market.
The most recent analyst rating on (GB:AREC) stock is a Hold with a £84.00 price target. To see the full list of analyst forecasts on Arecor Therapeutics PLC stock, see the GB:AREC Stock Forecast page.
Spark’s Take on GB:AREC Stock
According to Spark, TipRanks’ AI Analyst, GB:AREC is a Neutral.
Arecor Therapeutics’ score is driven by positive corporate events, including strategic partnerships and IP expansion, which bolster its market position. However, financial performance challenges, such as ongoing losses and cash flow issues, weigh heavily on the overall score. Technical analysis and valuation present a neutral outlook, reflecting the typical risks and opportunities in the biotech sector.
To see Spark’s full report on GB:AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a Cambridge, UK-based clinical-stage biotech company focused on developing superior therapeutics to reduce treatment burden and improve outcomes for people with diabetes, obesity and other cardiometabolic diseases. Its lead product, AT278, is an ultra-concentrated, ultra-rapid acting insulin co-developed with Sequel Med Tech, and it is also advancing an oral peptide delivery platform targeting GLP-1 receptor agonists.
Average Trading Volume: 27,614
Technical Sentiment Signal: Sell
Current Market Cap: £27.18M
Learn more about AREC stock on TipRanks’ Stock Analysis page.